Investment
Features
FeesSafety
Academy
More
Pluang+

Compare YieldMax COIN Option Income Strategy ETF (CONY) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

YieldMax COIN Option Income Strategy ETFTrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

YieldMax COIN Option Income Strategy ETF vs Inovio Pharmaceuticals Inc — how do they compare? YieldMax COIN Option Income Strategy ETF trades at $18.08, while Inovio Pharmaceuticals Inc trades at $0.76 (market cap $78.55M). Which is the better fit depends on your goals.

CONYINO
Sector
Income / Options OverlayHealth
52-Week High
$76.50$2.87
52-Week Low
$17.80$0.66
Market Cap
$78.55M
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

YieldMax COIN Option Income Strategy ETF

CONY trades at $18.05, down 0.11% with a bearish technical signal from moving averages. The ETF shows weekly dividend distributions but lacks fundamental valuation metrics. Recent news highlights investor losses despite high yield promises, with articles questioning the fund's long-term sustainability as a Coinbase proxy.

Outlook remains cautious due to structural concerns about the option income strategy capping upside potential. Investment opportunity centers on high distribution yields, but risks include underlying asset volatility and negative media sentiment questioning the fund's value proposition for long-term holders.

Inovio Pharmaceuticals Inc

INO shares trade at $0.74, up 10.24% today, but remain significantly below analyst consensus targets. The biotech firm shows improving operational trends with three consecutive quarterly earnings beats, though financials reveal substantial losses with -130% net margin. Technical indicators signal bearish momentum despite neutral oscillators. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with the company recently raising $20 million to fund operations.

Outlook hinges on FDA approval of INO-3107, representing a binary event that could drive substantial upside given the $3.25 consensus target. However, persistent cash burn, negative profitability metrics, and ongoing shareholder litigation pose significant risks. The stock offers high-risk, event-driven potential for speculative investors willing to accept regulatory and financial uncertainty.

Returns comparison

Trailing returns across standard periods

About YieldMax COIN Option Income Strategy ETF

CONY is an actively managed ETF that seeks to generate weekly income by selling call options on Coinbase (COIN) stock. It aims to provide high yield while maintaining exposure to the price movements of the crypto exchange.

Read more on CONY

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO